8-K/A: Moleculin Biotech Announces Positive Interim Data for Annamycin in AML and First Quarter 2024 Financial Results

Moleculin Biotech reports promising interim clinical trial results for Annamycin in acute myeloid leukemia (AML) and provides a financial update for the first quarter of 2024.

Summary

• Moleculin Biotech announced its financial results for the first quarter of 2024, alongside positive interim data from its MB-106 study of Annamycin in combination with Cytarabine (AnnAraC) for the treatment of AML.
• The MB-106 study showed a 62% composite complete remission (CRc) rate in first and second-line AML patients (N=13), with a 54% complete remission (CR) rate.
• The full MB-106 trial, with 20 subjects, achieved a 45% CRc rate across all lines of therapy, with a median durability of 4.9 months and climbing.
• The company has completed enrollment of 20 subjects in the MB-106 trial.
• Moleculin has received two new US patents related to Annamycin, extending patent protection until mid-2040.
• The company has been granted Orphan Drug Designation for Annamycin in AML by the European Medicines Agency (EMA), adding to existing US designations.
• Research and development expenses decreased to $4.3 million in Q1 2024 from $5.7 million in Q1 2023, primarily due to reduced clinical trial activity.
• General and administrative expenses also decreased slightly to $2.4 million in Q1 2024 from $2.6 million in Q1 2023.
• As of March 31, 2024, Moleculin had $16.8 million in cash and cash equivalents, which is expected to fund operations into the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and progress in patent protection and regulatory designations. The financial position is stable for the near term, but the company is still operating at a loss. The overall tone is optimistic and suggests a positive outlook for the company's future.

Positives

• The 62% CRc rate in 1st and 2nd line AML patients is a significant improvement over existing 2nd line treatments.
• The company has strengthened its intellectual property position with two new patents.
• The Orphan Drug Designation from the EMA provides potential market exclusivity and other benefits.
• The company has reduced its operating expenses compared to the same period last year.
• The company has sufficient cash to fund operations into the fourth quarter of 2024.
• The company has completed enrollment of 20 subjects in the MB-106 trial.

Negatives

• The company is still operating at a loss, with a net loss of $4.97 million for the quarter.
• Cash reserves have decreased from $23.55 million at the end of 2023 to $16.8 million as of March 31, 2024.
• The company is reliant on the success of its clinical trials to generate future revenue.

Risks

• Clinical trial results are preliminary and subject to change.
• The company's cash reserves may not be sufficient to fund operations beyond the fourth quarter of 2024.
• The company is dependent on regulatory approvals for its drug candidates.
• There is no guarantee that the company's drug candidates will be successful in clinical trials or receive regulatory approval.
• The company faces competition from other pharmaceutical companies developing treatments for AML.

Future Outlook

The company expects to complete the MB-106 Phase 1B/2 clinical trial and hold an End of Phase 2 meeting with the FDA in the first half of 2024, receive feedback from the FDA in the second half of 2024, initiate a pivotal trial in the first half of 2025, conclude the pivotal trial in the second half of 2026, and potentially submit an NDA in 2027. The company believes its current cash is sufficient to meet its projected operating requirements into the fourth quarter of 2024.

Management Comments

• Walter Klemp, Chairman and Chief Executive Officer of Moleculin, stated that the company is well-positioned for a highly productive End of Phase 2 meeting with the FDA to discuss the planned pivotal study of Annamycin for AML.
• Management believes that the results in 2nd line subjects fill a significant unmet need and that the CRc rate demonstrated by AnnAraC in 2nd line patients substantially exceeds the performance reported by any drug currently approved in the U.S. for use in 2nd line AML.

Industry Context

The announcement is significant in the context of the AML treatment landscape, where there is a high unmet need for effective therapies, particularly in relapsed or refractory cases. The positive interim data for Annamycin, especially in second-line patients, positions Moleculin as a potential competitor in this space. The company's focus on developing treatments that address drug resistance and cardiotoxicity aligns with current trends in oncology drug development.

Comparison to Industry Standards

• The 62% CRc rate in 1st and 2nd line AML patients treated with AnnAraC is notably higher than the results seen with currently approved 2nd line AML treatments. For example, drugs like Vyxeos (daunorubicin and cytarabine) and Glasdegib have shown lower response rates in similar patient populations.
• While specific comparative data for all 2nd line AML treatments is complex and varies across trials, the reported CRc rate for AnnAraC appears to be a significant improvement, suggesting a potential for a new standard of care.
• Companies like Jazz Pharmaceuticals (Vyxeos) and Agios Pharmaceuticals (Tibsovo) are key players in the AML space, and Moleculin's Annamycin is showing promising results that could challenge these established treatments.

Stakeholder Impact

• Shareholders may view the positive clinical data and patent news favorably.
• Employees may be encouraged by the progress of the company's drug development programs.
• Patients with AML may benefit from the development of a new and potentially more effective treatment option.
• The company's financial stability is important for its suppliers and creditors.

Next Steps

• Complete the MB-106 Phase 1B/2 clinical trial.
• Hold an End of Phase 2 meeting with the FDA.
• Receive feedback from the FDA EOP2 Meeting.
• Initiate a pivotal trial.
• Conclude the pivotal trial.
• Potentially submit an NDA.

Key Dates

Keywords

Annamycin, AML, Acute Myeloid Leukemia, Clinical Trial, MB-106, MB-108, Orphan Drug Designation, FDA, EMA, Pharmaceutical, Biotech, Cancer, Oncology, Cytarabine, AnnAraC